Navigation Links
Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million
Date:1/24/2013

62,180$
(1,498)$
560,682Reimbursable out-of-pocket expenses46,96446,964Total revenues609,144--(1,498)607,646Costs and expenses:  Cost of revenue395,8413,613(3,697)395,757  Reimbursable out-of-pocket expenses46,96446,964  Selling, general and administrative92,823(9,013)(117)83,693  Depreciation and amortization30,423(1,178)(534)28,711  Goodwill impairment charge---Total costs and expenses566,051(10,191)3,613(4,348)555,125Income from operations43,09310,191(3,613)2,85052,521Other expense, net:  Interest expense, net1,1531,153  Foreign exchange transaction loss, net173173  Impairment of equity investment--  Gain on sale of investment--  Loss on sale of business--Other expense, net1,326---1,326Income before taxes and equity investee earnings41,76710,191(3,613)2,85051,195Taxes on income7,8703,223(1,111)88410,866Equity investee earnings--Net income $
33,897$
,968$
(2,502)$
,966$
40,329Basic earnings per share$
.63$
.13$
(0.05)$
.04$
.75Weighted average shares outstanding - basic53,698,33453,698,33453,698,33453,698,33453,698,334Diluted earnings per share$
.61$
.13$
(0.05)$
.04$
.73Weighted average shares outstanding - diluted55,197,96855,197,96855,197,96855,197,96855,197,968(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.(2) Reduction of inventory impairment based upon determination of actual impaired inventory.(3) Represents results of operations at sites that were closed during the period. COVANCE INC.GAAP to Pro Forma ReconciliationQ4 2011(Dollars in thousands, except per share data)(UNAUDITED)AdjustmentsGAAP Restructuring Activities (1)Other
Charges (2)Income Tax Items (3)Pro FormaNet revenues$
532,478$
532,478Reimbursable out-of-pocket expenses49,90749,907Total revenues582,385---582,385Costs and expenses:  Cost of revenue371,852371,852
'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Covance To Present At The William Blair 32nd Annual Growth Stock Conference
2. Covance Reports Second Quarter Pro Forma Net Revenue Of $538 Million, Pro Forma EPS Of $0.65 And Adjusted Net Orders Of $701 Million
3. Covance to Present at the Morgan Stanley Global Healthcare Conference
4. Covance Reports Third Quarter Pro Forma Net Revenue Of $542 Million, Pro Forma EPS Of $0.72 And Adjusted Net Orders Of $701 Million
5. Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
7. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
8. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
9. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
10. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
11. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BEVERLY HILLS, Calif. , Jan. 14, 2014 ... , offers Los Angeles a premier ... Duality laser and a $99 treatment special. Dr. Brandeis, focus ... medical technology and offering expert medical advice to all patients. ... a dramatic increase in the presence of tattoo regret and ...
(Date:1/14/2014)... 2014 Animal Emergency Critical Care, a LifeCentre partner practice, ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a ... Dr. Cole Taylor , are avid scuba divers. "As altitude ... when air is thin," states Dr Barnes. She goes on to ...
(Date:1/14/2014)... --  Oligomerix, Inc. , a privately held company ... Alzheimer,s disease (AD) and related neurodegenerative disorders, announced ... Valhalla, NY as of ... additional laboratory space at New York Medical College. ... development of small molecule drugs aimed specifically at ...
Breaking Medicine Technology:Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... EORTC 40983 (EPOC),Intergroup Study Results, CHICAGO, June ... phase III EORTC 40983 Intergroup study, or ... peri-operative (pre and post,surgery) FOLFOX4 (Eloxatin(R) (oxaliplatin ... for colon cancer,5-fluorouracil/leucovorin (5-FU/LV)) given to patients ...
... Phase II Study Results Presented at Society ... 04, 2007 /PRNewswire-FirstCall/ --,Immunomedics, Inc. , a ... treat cancer and other serious,diseases, today announced ... with the radioisotope,iodine-131, was found to be ...
Cached Medicine Technology:The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 2The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 3The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 4The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 5The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 6The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 7The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 8The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 9Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 2Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 3Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 4Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases 5
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... , ATLANTA, Sept. 4 Blue Cross Blue Shield of ... already available to its group life insurance beneficiaries by offering a new ... loved one - The Healing Book: Facing the Death and Celebrating ... published by Watering Can Press). , , The ...
... , , , ... Access(SM), the nation,s leading provider of vascular access management services, ... awarded the 2009 Gerald A. Beathard Fellowship in Interventional Nephrology. ... pioneers in Interventional Nephrology and Lifeline,s Vice President of Provider ...
... Kan., Sept. 4 The path to poor hand sanitation is ... North Carolina State Universities. , , As college ... the researchers said students, actions will speak louder than words. , ... hands," said Douglas Powell, an associate professor of food safety at ...
... researchers have developed a new approach to identify ... to drugs and how they become resistant. This ... result in leukemia and associating specific mutations with ... how drug resistance occurs in leukemia and other ...
... ABBOTT PARK, Ill., Sept. 4 For the fourth consecutive year, Abbott (NYSE: ... to Launch a Career" by BusinessWeek magazine. The list highlights ... year, Abbott moved up to No. 13, and was once again the top-ranked ... list every year since BusinessWeek initiated the list in 2006. , ...
... suggests officials might need to rethink strategies , ... that officials in the United States, United Kingdom and ... because the current strategies -- emphasizing healthy diets and ... online Sept. 4 in BMJ , Australian researchers ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Georgia Offers The Healing Book to Help Young Life Insurance Beneficiaries Cope with Losing a Loved One 2Health News:Gerald A. Beathard Fellowship Awarded to Dr. Stephen Osaguona 2Health News:Gerald A. Beathard Fellowship Awarded to Dr. Stephen Osaguona 3Health News:Getting College Students To Wash Hands, Halt Disease, Requires Giving Them Proper Tools and Spreading The Word In Ways That Get Attention, Say K-State Expert and Colleague 2Health News:New research strategy for understanding drug resistance in leukemia 2Health News:New research strategy for understanding drug resistance in leukemia 3Health News:Abbott Again Named One of the 'Best Places to Launch a Career' by BusinessWeek 2Health News:Abbott Again Named One of the 'Best Places to Launch a Career' by BusinessWeek 3
Empore Sealing Tape Pads are ideal for covering a 96 well plate during storage or transfer to another work station. Not intended for use with auto-injectors....
Mylar Plate Sealers 100/Box...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
For use with 96-well plates, catalog # 410150...
Medicine Products: